{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:27:42Z","timestamp":1789043262963,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novartis Farma"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clml.2020.04.015","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T04:11:44Z","timestamp":1588219904000},"page":"588-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications"],"prefix":"10.1016","volume":"20","author":[{"given":"Alessandra","family":"Malato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mendicino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novella","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.015_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428194.2013.794269","article-title":"Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation","volume":"55","author":"Santos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.015_bib2","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/bcj.2011.36","article-title":"How I treat splenomegaly in myelofibrosis","volume":"1","author":"Cervantes","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.04.015_bib3","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/blood.V97.7.2180","article-title":"Splenectomy and hemopoietic stem cell transplantation for myelofibrosis","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.015_bib4","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.015_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.04.015_bib6","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal","year":"2014","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.clml.2020.04.015_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/jso.1064","article-title":"Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases","volume":"77","author":"Akpek","year":"2001","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clml.2020.04.015_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0145-2126(00)00018-7","article-title":"Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients","volume":"24","author":"Bouabdallah","year":"2000","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2020.04.015_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","article-title":"Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia","volume":"103","author":"Elliott","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.015_bib10","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/1097-0142(19860915)58:6<1204::AID-CNCR2820580605>3.0.CO;2-G","article-title":"Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea","volume":"58","author":"Wagner","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.04.015_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12185-016-1940-3","article-title":"Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients","volume":"103","author":"Kitanaka","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.04.015_bib12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-016-2638-6","article-title":"Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study","volume":"95","author":"Gratwohl","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.04.015_bib13","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1080\/10428194.2017.1321747","article-title":"Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis","volume":"58","author":"Kalman","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.015_bib14","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1182\/blood.V124.21.3170.3170","article-title":"Splenic irradiation and a reduced-intensity conditioning regimen prior to allogeneic stem-cell transplantation for myelofibrosis","volume":"124","author":"Vyas","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.015_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2020.04.015_bib16","first-page":"8751329","article-title":"Usefulness of low-dose splenic irradiation prior to reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in elderly patients with myelofibrosis","volume":"2016","author":"Matsubara","year":"2016","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.clml.2020.04.015_bib17","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.015_bib18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ajh.24881","article-title":"Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.015_bib19","doi-asserted-by":"crossref","first-page":"E235","DOI":"10.1002\/ajh.25203","article-title":"Early thrombotic events and preemptive systemic anticoagulation following splenectomy for myelofibrosis","volume":"93","author":"Mudireddy","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.015_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2010.08527.x","article-title":"Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34+ haematopoietic progenitor cells in primary myelofibrosis","volume":"152","author":"Massa","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.015_bib21","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2012.249","article-title":"Effects of spleen status on early outcomes after hematopoietic cell transplantation","volume":"48","author":"Akpek","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib22","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.015_bib23","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","article-title":"Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)","volume":"152","author":"Robin","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.015_bib25","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bmt.2010.14","article-title":"The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study","volume":"45","author":"Stewart","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib27","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JOP.2016.013268","article-title":"Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: a practical review","volume":"12","author":"Farhadfar","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.04.015_bib30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.015_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0683-1","article-title":"The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review","volume":"55","author":"Tiribelli","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.04.015_bib32","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.04.015_bib33","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1038\/bcj.2014.84","article-title":"Definition and management of ruxolitinib treatment failure in myelofibrosis","volume":"4","author":"Pardanani","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.04.015_bib34","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030210X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502030210X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:24Z","timestamp":1761870924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502030210X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S215226502030210X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}